John Heymach, MD, PhD

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, MD, PhD.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and improved patient quality of life.

The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.

The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.

A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.